November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Nelson Dusetti: Wearing the purple ribbon to support everyone affected by Pancreatic Cancer
Nov 23, 2024, 12:15

Nelson Dusetti: Wearing the purple ribbon to support everyone affected by Pancreatic Cancer

Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM, reshared a post by Ligue contre le cancer on LinkedIn, adding:

“Today, on World Pancreatic Cancer Day, we wear the purple ribbon to show our support for everyone affected by this disease and their families.

Pancreatic cancer remains one of the most challenging to diagnose and treat, but thanks to the invaluable support of the Ligue contre le cancer, research is advancing every day.

The Pancreatic Cancer Team at CRCM – Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, we are fully engaged in the fight against pancreatic cancer, working tirelessly on innovative research to improve early diagnosis and treatment options.

Together, we can improve treatments and bring new hope.

A heartfelt thank you to the Ligue for their commitment and to everyone mobilizing for this cause.

Click here to learn more about their initiatives.”

Quoting Ligue contre le cancerb‘s post:

“Pancreatic cancer is now a significant public health issue. It is steadily increasing worldwide, and its progression is such that it could become the second leading cause of cancer-related mortality in the European Union by 2030.

Pancreatic cancer remains very challenging to manage, and its treatment has yet to benefit from true personalization. However, the findings of Nelson Dusetti‘s research, supported by the Ligue, could change the game. 

Thanks to your support, we can back large-scale projects like this one. 

Click here for all the info.”

Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.